Nsc232003

Manufactured by MedChemExpress

NSC232003 is a small molecule compound. It is intended for laboratory research use only.

Automatically generated - may contain errors

Lab products found in correlation

Ab2828, by Abcam (1 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Streptomycin, by Thermo Fisher Scientific (1 mentions) Recombinant tgf β1, by Thermo Fisher Scientific (1 mentions) Mrc 5 cells, by American Type Culture Collection (1 mentions) Nih3t3 cells, by Thermo Fisher Scientific (1 mentions) Beclin1 sirna, by GenePharma (1 mentions) Bish1475, by Sartorius (1 mentions) Mrc 5 cells, by Thermo Fisher Scientific (1 mentions) Nih3t3, by American Type Culture Collection (1 mentions) Ribofect cp reagent, by RiboBio (1 mentions)

2 protocols using nsc232003

Epigenetic Regulation Protein Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

5-aza-2’-deoxycytidine (5-AzadC, A3656), TNF-α (GF314) and epigallocatechin-3-gallate (EGCG, E4143) were purchased from Sigma Aldrich. NSC232003 was purchased from MedChemExpress (HY-103236). Antibodies against CREB (sc-186, RRID:AB_2086021), CREM (sc-440, RRID:AB_673599), ATF-1 (sc-28673, RRID:AB_2274416), MBD4 (sc-10753, RRID:AB_2250279) and purified rabbit IgG (sc-2027, RRID:AB_737197) were purchased from Santa Cruz Biochemical. Antibodies against MBD1 (pAb-078-050) and UHRF1 for ChIP applications (C154110258-100) were purchased from Diagenode. Antibodies against MBD2/3 (07-199, RRID:AB_310423), Kaiso (05-659, RRID:AB_309884) and UHRF1 for EMSA and western blotting (MABE308) were purchased from Upstate/Millipore. Antibodies against MeCP2 (ab2828, RRID:AB_2143853) and RBP-JK (ab33065, RRID:AB_778156) were purchased from Abcam. Antibody against RNA polymerase II (RNAPII) (14958, RRID:AB_2687876) was purchased from Cell Signaling Technology. Secondary antibodies (7074, RRID:AB_2099233 and 7076, RRID:AB_330924) were purchased from Cell Signaling Technology.

Verdikt R., Bendoumou M., Bouchat S., Nestola L., Pasternak A.O., Darcis G., Avettand-Fenoel V., Vanhulle C., Aït-Ammar A., Santangelo M., Plant E., Douce V.L., Delacourt N., Cicilionytė A., Necsoi C., Corazza F., Passaes C.P., Schwartz C., Bizet M., Fuks F., Sáez-Cirión A., Rouzioux C., De Wit S., Berkhout B., Gautier V., Rohr O, & Van Lint C. (2022). Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. eBioMedicine, 79, 103985.

+ Open protocol

+ Expand

Regulation of Fibroblast Activation by UHRF1

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human fibroblasts (MRC-5 cells) and mouse fibroblasts (NIH/3T3) were purchased from ATCC. The PLFs were isolated from the lung of the C57BL/6 mouse. MRC-5 cells were maintained in Minimum Essential Medium (Life Technologies/Gibco), and NIH/3T3 cells and PLFs were maintained in DMEM (Life Technologies/Gibco), which contained 10% fetal bovine serum (BISH1475, Biological Industries) and antibiotics (penicillin and streptomycin, Life Technologies/Gibco). All the cells were cultured at 37°C with 5% CO₂. Cells were treated with 5 ng/mL recombinant TGF-β1 (Peprotech) for 48 hours to induce fibroblast activation. To inhibit UHRF1 expression, fibroblasts were treated with 15 μM NSC232003 for 4 hours after TGF-β1 treatment.
UHRF1 siRNA, beclin 1 siRNA, and control siRNA were synthesized by GenePharm. UHRF1 plasmid and beclin 1 plasmid were synthesized by Genery. Cells were transfected using riboFECTCP Reagent (Ribobio) according to the manufacturer’s protocol. The UHRF1 siRNA and beclin 1 siRNA sequences are shown in Supplemental Table 1. The UHRF1 inhibitor NSC232003 was phased from MedChemExpress.

Cheng D., Wang Y., Li Z., Xiong H., Sun W., Xi S., Zhou S., Liu Y, & Ni C. (2022). Liposomal UHRF1 siRNA shows lung fibrosis treatment potential through regulation of fibroblast activation. JCI Insight, 7(22), e162831.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!